EUCTR2006-005508-14-DE进行中（未招募）不适用
A randomized, , double-blind, single centre, intra-individual comparison study with repeated application to assess the wound-healing efficacy of a 5 % Dexpanthenol ointment compared with placebo in patients with superficial, abrasive wounds.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female caucasian
- •Age 18 to 45
- •Skin type I to IV
- •Willingness to actively participate in the study and to comply with the study procedures as defined in the study protocol
- •Signed written informed consent
- •Negative urine pregnancy test (in female subjects of childbearing potential)
- •For female subjects of childbearing potential: use of a reliable contraceptive method (e.g. contraceptive pills, intrauterine contraceptive device, implants).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Active skin disease, moles, tattoos, strong pigmentation at the test area or scars in the test area that would influence the visual scoring
- •History of keloids and hypertrophic scars
- •History of plaster sensitivity
- •Intake of drugs interfering with the immune system (e.g. antiphlogistics, corticosteroids, immunosuppressants, and antihistamines) within 30 days before day 1 as well as during the study.
- •Concomitant therapy with substances affecting blood coagulation (e.g. acetylsalicylic acid, anticoagulants, diuretics) within up to 14 days prior to the start of the study as well as during the study
- •Any condition or treatment (within 14 days prior to the start as well as during the study) which might influence the study (e.g. diabetes, dysfunction of blood clotting)
- •Change of hormonal contraception within 3 months prior to enrolment and during the study
- •Application of any topical treatment (e.g. moisturizers, sun protection) at the test areas during the conduct of the study (until day 36)
- •Intensive UV-light exposure within two weeks before the beginning as well as during the study
- •Removal of axillary lymph nodes
- •Allergy to the ingredients of the test product
- •Pregnancy or lactation
- •Any illness on account of which the subject should not participate in the study in the opinion of the investigator
- •Any history of drug addiction or alcoholism in the past 3 years
- •Infectious diseases (e.g. hepatitis or AIDS)
- •Participation in a clinical trial within the last 30 days prior to enrolment
研究者
相似试验
已完成
不适用
A single-center, randomized, double-blind, double-dummy, placebo- and active-controlled, 4-way cross-over study to assess next-day driving performance following single and multiple evening administrations of ACT-541468 in middle-aged and elderly subjects.InsomniaNL-OMON48154Idorsia Pharaceuticals Ltd.56
已完成
不适用
Impact of topical application of Test Product on skin hydration, moisturisation and microorganisms regulation.CTRI/2020/02/023247Tata Chemicals Ltd33
进行中（未招募）
不适用
A single centre, randomised, double-blind, double-dummy, placebo-and active-controlled, 3-way cross-over study to evaluate the 24 hour FEV1 profile of a single dose of CHF 5188 pMDI (400/4 mcg QD) (fixed combination budesonide/carmoterol 200/2 mcg) in adults patients with moderate or severe persistent asthmaModerate or Severe Persistent AsthmaMedDRA version: 9.1Level: LLTClassification code 10003555Term: Asthma bronchialEUCTR2008-001773-15-GBChiesi Farmaceutici SpA42
已完成
不适用
A single-center, randomized, double-blind, two-period cross-over study to investigate the effect of a single intravenous dose of rifampicin on the pharmacokinetics of ACT-246475 in healthy subjects.Acute myocardial infarctionNL-OMON46064Idorsia Pharmaceuticals Ltd14
已完成
不适用
A single-center, randomized, double-blind, two-period cross-over study to investigate the effect of rifampicin on the pharmacokinetics of clazosentan in healthy male subjects.NL-OMON45870Idorsia Pharmaceuticals Ltd14